P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1 d.
12. 10., 9:49:20 GMT+8 · SGD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre P8A…
Trh. kap.
32,37 mil.
Priem. obj.
1,32 tis.
Objem
0,00
Max. za 52 týž.
0,26 SGD
Min. za 52 týž.
0,10 SGD
Výnosy na akciu
-0,04 SGD
Akcie v obehu
267,53 mil.
Počet zamestnancov
111
Trh. kap.
32,37 mil.
Priem. obj.
1,32 tis.
Objem
0,00
Max. za 52 týž.
0,26 SGD
Min. za 52 týž.
0,10 SGD
Výnosy na akciu
-0,04 SGD
Akcie v obehu
267,53 mil.
Počet zamestnancov
111
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Simply Wall Street
·
pred 4 minútami
Is Intellia Therapeutics (NTLA) Cheap Or Pricey On Its New Chief Medical Officer Appointment?
Capital Brief
·
pred 29 minútami
Australian shares to open lower as chip selloff weighs on Nasdaq
Yahoo Finance
·
pred 12 hodinami
Michael Burry Warns of a Stock Market ‘Supervolcano’
AOL.com
·
pred 8 hodinami
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
Profil
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Informácie o subjekte Cordlife Group Ltd
Generálny riaditeľYiu Pang Fai
Zamestnanci111
Dátum založenia2. 5. 2001
Hlavné sídlo-
OdvetvieHealth care provider
Webcordlife.com